Skip to main content

Biocon Secures U.S. FDA Approval for Pebrilzo, Its Fifth Oncology Biosimilar, with U.S. Launch Expected in 2028

Biocon Secures U.S. FDA Approval for Pebrilzo, Its Fifth Oncology Biosimilar, with U.S. Launch Expected in 2028

Biocon Limited has received U.S. Food and Drug Administration (FDA) approval for Pebrilzo™ (pertuzumab-qcay), a biosimilar to Roche’s Perjeta® (pertuzumab), marking a significant milestone in the company’s oncology business and its efforts to expand access to affordable cancer treatments.

Pebrilzo is a monoclonal antibody indicated for HER2-positive breast cancer. It works by blocking HER2 receptors on cancer cells, helping address a subtype of breast cancer associated with aggressive tumour growth.

With this approval, Pebrilzo becomes Biocon’s fifth oncology biosimilar to receive U.S. FDA approval, joining its existing portfolio of Ogivri® (trastuzumab-dkst), Jobevne® (bevacizumab-nwgd), Fulphila® (pegfilgrastim-jmdb) and Aukelso® (denosumab-kyqq).

Biocon has also announced a global settlement and licensing agreement with Genentech, securing the earliest licensed U.S. commercial launch date for Pebrilzo in the third quarter of calendar year 2028.

Commenting on the development, Shreehas Tambe, CEO and Managing Director of Biocon Limited, said the approval represents another important milestone in the company's commitment to expanding access to high-quality, affordable biosimilars, particularly for patients facing the clinical and financial challenges associated with HER2-positive breast cancer.

The development follows a positive opinion issued in September by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP), recommending marketing authorization for Biocon's pertuzumab biosimilar under the Pebrilzo brand in Europe.


The U.S. FDA approval was supported by a comprehensive data package covering structural and functional characterization, analytical similarity and comparative clinical pharmacokinetic studies. The findings established high similarity to the reference product, with no clinically meaningful differences in quality, safety, efficacy or immunogenicity.

Beyond Pebrilzo, Biocon is advancing its oncology pipeline with proposed biosimilars to trastuzumab/hyaluronidase, nivolumab and pembrolizumab, expanding its presence across HER2-directed treatments and immuno-oncology.

The approval comes amid a substantial need for breast cancer treatment options in the United States. Around 320,000 women are expected to be diagnosed with breast cancer in 2026, with approximately 20% of cases classified as HER2-positive.

With Pebrilzo, Biocon further strengthens its position in the global biosimilars market, while preparing to expand its oncology portfolio into another important treatment segment following the anticipated U.S. launch in 2028.